BioMarin Announces Board Leadership Transition

BioMarin Pharmaceutical Inc. said that the Board of Directors has appointed Ian T. Clark as Chair of the Board, subject to his election at the company's Annual Meeting of Stockholders on June 2, 2026. Mr. Clark will succeed Richard A. Meier, who is retiring after two decades on the Board, and the appointment will become effective immediately following the Annual Meeting.

Mr. Clark joined BioMarin's Board in 2025 and brings extensive board, governance and executive leadership experience across the global biopharmaceutical industry. He has served on the boards of a number of public biopharmaceutical companies, including roles as lead independent director and chair. He was Chief Executive Officer of Genentech and a member of Genentech's Board of Directors from 2010 to 2016.

"I am excited to step into this role as BioMarin enters its next phase of growth as a leading rare disease company operating at scale in 80 countries," said Mr. Clark. "With two recent acquisitions, BioMarin has the potential to unlock significant value for all stakeholders: employees, shareholders and, most importantly, patients." 

Mr. Meier joined BioMarin's Board in 2006, playing a key role in the company's evolution. He was Lead Independent Director before being elected Chair in 2023. During this period, profitability improved meaningfully, with significant expansion in non-GAAP operating margin, earnings-per-share growth and substantial cash flow generation.

"BioMarin enters this next chapter with excellent leadership, strategic clarity and a strong foundation for continued success," said Mr. Meier. "The company is well positioned to build on this momentum in the years ahead. It has been an honor to serve on BioMarin's Board over the past two decades and I am pleased to hand the reins to Ian."

Alexander Hardy, President and Chief Executive Officer of BioMarin, said, "Randy has helped guide BioMarin through a period of meaningful growth and transformation, and we are grateful for his leadership and service. I am pleased to welcome Ian to his new role. Ian brings substantial board and executive experience, and I look forward to partnering with him as we continue executing our strategy for patients around the world."

About BioMarin